DEM BioPharma Funding Round

6/23/2022

Venture Equity

$70,000,000

Undisclosed

DEM Bio is focused on accessing the largely untapped opportunity around macrophage biology and innate immune system pathways to discover potent DEM and EM signals on cancers and expand the therapeutic potential of the field beyond the relatively small number of signals targeted by current investigational therapies.

Private & Independent

Biopharmaceutical

lexandria LaunchLabs, One Kendall Square, Building 200, 001
Cambridge, MA 02139
USA

Undisclosed

DEM Bio is pioneering the next generation of immunotherapeutics designed to unleash macrophages and other myeloid effector cells to eliminate tumors by targeting novel 'don't eat me' (DEM) and 'eat me' (EM) signals on cancer cells and macrophages. Our proprietary CHoMP� platform (Co-culture with Human Myeloid Phagocytes) will be used to identify unexplored DEM and EM signals in a systematic and unbiased manner via inter-cellular CRISPR screening using tumor cells, primary macrophages, and other innate immune effector cells. DEM Bio was co-founded by the Longwood Fund and distinguished scientists Drs. Jonathan Weissman, Kipp Weiskopf, and Michael Bassik.